Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$217.92-0.2%$200.86$163.81▼$221.76$384.97B0.536.47 million shs5.16 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%+2.85%+5.69%+14.40%+12.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$217.92-0.2%$200.86$163.81▼$221.76$384.97B0.536.47 million shs5.16 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%+2.85%+5.69%+14.40%+12.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.92Moderate Buy$218.760.39% UpsideCurrent Analyst Ratings BreakdownLatest ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025ABBVAbbVieCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$215.00 ➝ $245.009/12/2025ABBVAbbVieWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$240.00 ➝ $260.009/12/2025ABBVAbbVieBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$215.00 ➝ $240.008/25/2025ABBVAbbVieRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/12/2025ABBVAbbViePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$231.008/11/2025ABBVAbbViePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/7/2025ABBVAbbVieDaiwa AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/7/2025ABBVAbbVieDaiwa Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$214.008/1/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$250.00 ➝ $255.008/1/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$216.00 ➝ $227.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$58.33B6.60$14.91 per share14.62$1.90 per share114.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.10103.7715.591.406.45%699.66%13.64%10/29/2025 (Estimated)Latest ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.01%N/A312.38%53 YearsLatest ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/5/2025ABBVAbbViequarterly$1.643.08%10/15/202510/15/202511/14/20256/20/2025ABBVAbbViequarterly$1.643.54%7/15/20257/15/20258/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.740.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.77 billionOptionableABBV HeadlinesRecent News About These CompaniesBiotech Stocks To Follow Now - September 14thSeptember 15 at 1:00 PM | marketbeat.comAbbVie loses bid to block 340B law in MississippiSeptember 15 at 10:49 AM | pharmaphorum.comPWhat would a sea change in drug advertising mean for big-spending AbbVie?September 15 at 10:49 AM | chicagobusiness.comCAbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in AlbertaSeptember 15 at 10:49 AM | finance.yahoo.comAbbVie (NYSE:ABBV) Given New $245.00 Price Target at Cantor FitzgeraldSeptember 15 at 8:50 AM | marketbeat.com21 West Wealth Management LLC Makes New $239,000 Investment in AbbVie Inc. $ABBVSeptember 15 at 6:07 AM | marketbeat.comGoldstone Financial Group LLC Has $1.68 Million Holdings in AbbVie Inc. $ABBVSeptember 15 at 5:57 AM | marketbeat.comLingohr Asset Management GmbH Has $436,000 Stock Holdings in AbbVie Inc. $ABBVSeptember 15 at 5:48 AM | marketbeat.comLegacy Private Trust Co. Raises Stock Position in AbbVie Inc. $ABBVSeptember 15 at 5:39 AM | marketbeat.comAbbVie Inc. $ABBV Shares Sold by Quintet Private Bank Europe S.A.September 15 at 5:31 AM | marketbeat.comGradient Investments LLC Grows Stock Holdings in AbbVie Inc. $ABBVSeptember 15 at 5:30 AM | marketbeat.comAdams Asset Advisors LLC Cuts Stock Holdings in AbbVie Inc. $ABBVSeptember 15 at 5:30 AM | marketbeat.comCultivar Capital Inc. Acquires New Stake in AbbVie Inc. $ABBVSeptember 15 at 5:12 AM | marketbeat.comParallel Advisors LLC Lowers Stake in AbbVie Inc. $ABBVSeptember 15 at 5:05 AM | marketbeat.comJones Financial Companies Lllp Has $36.79 Million Stake in AbbVie Inc. $ABBVSeptember 15 at 3:38 AM | marketbeat.comSen. John Boozman Sells Off Shares of AbbVie Inc. (NYSE:ABBV)September 15 at 2:11 AM | marketbeat.comWilliam Blair Comments on AbbVie's Q3 Earnings (NYSE:ABBV)September 15 at 2:09 AM | marketbeat.comBiotech Stocks To Consider - September 13thSeptember 14 at 1:07 PM | marketbeat.comCapital Market Strategies LLC Sells 1,975 Shares of AbbVie Inc. $ABBVSeptember 14 at 6:51 AM | marketbeat.comAbbVie Inc. $ABBV Shares Acquired by Wealth Alliance Advisory Group LLCSeptember 14 at 6:45 AM | marketbeat.comTeamwork Financial Advisors LLC Has $595,000 Stock Holdings in AbbVie Inc. $ABBVSeptember 14 at 6:45 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABBV Company DescriptionsAbbVie NYSE:ABBV$217.92 -0.42 (-0.19%) Closing price 03:59 PM EasternExtended Trading$217.40 -0.52 (-0.24%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
